+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Capecitabine Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • July 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5393428
Capecitabine is a pyrimidine analog (pentoxycarbonyl-deoxy-cytosine nucleoside) that has anti-tumor activity to inhibit a variety of solid tumors, including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA was approved to enter the Chinese market in 2001. By 2020, there are several manufacturers in the Capecitabine market in China.





According to the market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital's overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.

The analyst expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.

Topics Covered:

  • The impact of COVID-19 on China's Capecitabine market
  • Sales value of China's Capecitabine 2016-2020
  • Competitive landscape of China's Capecitabine market
  • Prices of Capecitabine in China
  • Prices of Capecitabine in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Capecitabine market
  • Prospect of China's Capecitabine market from 2021 to 2025
Frequently Asked Questions about the Chinese Capecitabine Market

What is the estimated value of the Chinese Capecitabine Market?

The Chinese Capecitabine Market was estimated to be valued at CNY 871.49 Million in 2016.

What is the growth rate of the Chinese Capecitabine Market?

The growth rate of the Chinese Capecitabine Market is 7.0%, with an estimated value of CNY 1611.57 Million by 2025.

What is the forecasted size of the Chinese Capecitabine Market?

The Chinese Capecitabine Market is estimated to be worth CNY 1611.57 Million by 2025.

Who are the key companies in the Chinese Capecitabine Market?

Key companies in the Chinese Capecitabine Market include Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA), Jiangsu Hengrui Medicine Co,.Ltd. (Aibin), Qilu Pharmaceutical Co., Ltd. (Zuolun), Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu) and La Roche Inc (XELODA).

Table of Contents

1 Relevant Concepts of Capecitabine
1.1 Indications for Capecitabine
1.2 Development history of Capecitabine in China
1.3 Approval Information of Capecitabine in China
1.4 The Impact of COVID-19 on Capecitabine sales in China
2 Sales of Capecitabine in China, 2016-2020
2.1 Sales Value of Capecitabine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Capecitabine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Capecitabine by Dosage Form in China, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Capecitabine Manufacturers in China, 2016-2020
3.1 Market Share Analysis of Major Capecitabine Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Roche Pharmaceuticals Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of XELODA (Shanghai Roche Pharmaceuticals Co., Ltd.’s Capecitabine) in China
3.3 Jiangsu Heng Rui Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Aibin (Jiangsu Hengrui Medicine Co,.Ltd.’s Capecitabine) in China
3.4 Qilu Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Zuolun (Qilu Pharmaceutical Co., Ltd.’s Capecitabine) in China
3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Shoufu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Capecitabine) in China
3.6 Hoffmann-La Roche Inc
3.6.1 Enterprise Profile
3.6.2 Sales of XELODA (Hoffmann-La Roche Inc’s Capecitabine) in China
4 Prices of Capecitabine of Different Manufacturers in China, 2020-2021
4.1 Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
4.2 Jiangsu Hengrui Medicine Co,.Ltd. (Aibin)
4.3 Qilu Pharmaceutical Co., Ltd. (Zuolun)
4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
4.5 Hoffmann-La Roche Inc (XELODA)
5 Prospect of Chinese Capecitabine drug Market, 2021-2025
5.1 Influential Factors of Chinese Capecitabine Market Development
5.1.1 The Impact of COVID-19 on Chinese Capecitabine Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Capecitabine Tablets Registration in China
Chart Sales Value of Capecitabine Tablets over the World
Chart Sales Value of Capecitabine Tablets in China, 2016-2020
Chart Sales Value of Capecitabine Tablets in China by Region, 2016-2020
Chart Sales Volume of Capecitabine Tablets in China, 2016-2020
Chart Sales Volume of Capecitabine Tablets in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Capecitabine Manufacturers in China, 2016-2020
Chart Sales Value and Volume of XELODA (Shanghai Roche Pharmaceuticals Co., Ltd.’s Capecitabine) in China, 2016-2020
Chart Sales Value and Volume of Aibin in China, 2016-2020
Chart Sales Value and Volume of Zuolun in China, 2016-2020
Chart Sales Value and Volume of Shoufu in China, 2016-2020
Chart Sales Value and Volume of XELODA (Hoffmann-La Roche Inc’s Capecitabine) in China, 2016-2020
Chart Referential Prices of XELODA (Shanghai Roche Pharmaceuticals Co., Ltd.’s Capecitabine) in China, 2020-2021
Chart Referential Prices of Aibin in China, 2020-2021
Chart Referential Prices of Zuolun in China, 2020-2021
Chart Referential Prices of Shoufu in China, 2020-2021
Chart Referential Prices of XELODA (Hoffmann-La Roche Inc’s Capecitabine) in China, 2020-2021
Chart Forecast on Sales Value of Capecitabine in China, 2021-2025
Chart Forecast on Sales Volume of Capecitabine in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
  • Jiangsu Hengrui Medicine Co,.Ltd. (Aibin)
  • Qilu Pharmaceutical Co., Ltd. (Zuolun)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
  • Hoffmann-La Roche Inc (XELODA)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...